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        Herpesviruses are an ancient virus family whose 
members have long histories of coevolution 
with their host species (  1  ). A hallmark of her-
pesvirus biology is the ability to colonize a naive 
host through the productive (lytic) infection of 
permissive cells, usually at a mucosal site of virus 
transmission, and thereafter to persist within that 
host as a nonproductive (latent) infection of a 
diff  erent specialized cell type. Persistence within 
the now-immune host is achieved through the 
down-regulation of all viral antigen expression 
in latently infected cells. Subsequently, occa-
sional reactivations from latency can serve to re-
establish the foci of virus replication at mucosal 
sites, providing a source of infectious virions for 
transmission to other individuals. 
  In the best studied system, HSV, a member 
of the     -herpesvirus subfamily establishing la-
tency in neurons, the possibilities of successful 
reactivation are increased if the virus initially 
establishes a high latent virus genome load 
(  2, 3  ); this in turn is reliant on the level of virus 
replication initially achieved during primary in-
fection of the naive host (  3, 4  ). Because the host 
CD8     T cell response is the principle means of 
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      1-Herpesviruses such as Epstein-Barr virus (EBV) have a unique ability to amplify virus 
loads in vivo through latent growth-transforming infection. Whether they, like     - and 
    -herpesviruses, have been driven to actively evade immune detection of replicative (lytic) 
infection remains a moot point. We were prompted to readdress this question by recent 
work (Pudney, V.A., A.M. Leese, A.B. Rickinson, and A.D. Hislop. 2005.   J. Exp. Med.   
201:349  –  360; Ressing, M.E., S.E. Keating, D. van Leeuwen, D. Koppers-Lalic, I.Y. Pappworth, 
E.J.H.J. Wiertz, and M. Rowe. 2005.   J. Immunol.   174:6829  –  6838) showing that, as 
EBV-infected cells move through the lytic cycle, their susceptibility to EBV-specifi  c CD8     
T cell recognition falls dramatically, concomitant with a reductions in transporter associated 
with antigen processing (TAP) function and surface human histocompatibility leukocyte 
antigen (HLA) class I expression. Screening of genes that are unique to EBV and closely 
related     1-herpesviruses of Old World primates identifi  ed an early EBV lytic cycle gene, 
BNLF2a, which effi  ciently blocks antigen-specifi  c CD8     T cell recognition through HLA-A  –  , 
HLA-B  –  , and HLA-C  –  restricting alleles when expressed in target cells in vitro. The small 
(60  –  amino acid) BNLF2a protein mediated its effects through interacting with the TAP 
complex and inhibiting both its peptide- and ATP-binding functions. Furthermore, this 
targeting of the major histocompatibility complex class I pathway appears to be conserved 
among the BNLF2a homologues of Old World primate     1-herpesviruses. Thus, even the 
acquisition of latent cycle genes endowing unique growth-transforming ability has not 
liberated these agents from evolutionary pressure to evade CD8     T cell control over virus 
replicative foci. 1864 CD8     T CELL IMMUNE EVASION BY EBV | Hislop et al.
specifi  c for immediate early  –  , early  -  , or late-expressed EBV 
antigens indicated much poorer presentation as the lytic cycle 
progressed (  13  ). In this paper, we show that EBV and other 
Old World LCVs have indeed acquired an evasion strategy 
that specifi  cally targets the peptide transporter TAP, thus limit-
ing the supply of antigenic fragments to MHC class I mole-
cules and, ultimately, their presentation to CD8     T cells. 
    RESULTS   
  Screening of     1-herpesvirus  –  specifi  c lytic cycle genes 
for inhibition of CD8     T cell recognition 
  We reasoned that any specifi  c immune evasion function as-
sociated with EBV replication would most likely map to a 
lytic cycle gene restricted to the     1-herpesvirus (LCV) genus. 
Genomic sequences of HSV, CMV, and Kaposi  ’  s sarcoma  –
  associated herpesvirus, the prototypic     ,     , and     2 human 
herpesviruses, were aligned alongside those of two Old World 
    1 viruses, EBV and rhesus LCV, and with the recently dis-
covered New World     1 virus of marmosets. This identifi  ed 
11 LCV-specifi  c genes that were present in the Old World 
viruses, some of which were also found in the New World 
virus. 4 out of these 11 genes are centrally positioned in the 
EBV genome; 2 of the 4, BLLF1 and BZLF2, encode viral en-
velope glycoproteins known to be involved in B cell entry, 
whereas the other 2, BLLF2 and BHLF1, were of particu-
lar interest because their functions are unknown. The other 
seven LCV-specifi  c genes all lie within a 35-kb region at 
the right-hand end of the EBV genome and are identifi  ed 
as open blocks in the genome maps shown in   Fig. 1  .   Two of 
these, BARF1 and BALF1, have homologies to the cellular 
CSF-1 receptor and bcl2 genes, respectively, implying func-
tions other than the interception of antigen processing path-
ways, whereas a third gene, LF3, is deleted in the B95.8 virus 
strain that displays HLA class I down-regulation in the lytic 
cycle. The remaining unique genes in this region, BNLF2a, 
BNLF2b, BILF1, and BILF2, were selected for further study 
alongside BLLF2 and BHLF1. 
controlling this initial replication, any factor restricting the 
effi   ciency of that control would be to the advantage of the 
virus. Indeed, HSV was the fi  rst herpesvirus in which a CD8     
T cell evasion mechanism was recognized. This involves an 
immediate early protein of the HSV lytic cycle, ICP47, which 
inhibits the peptide transporter associated with antigen pro-
cessing (TAP) by acting as a pseudosubstrate preventing pep-
tide binding and transport. Consequently, TAP cannot pump 
potentially antigenic peptides from proteasomal digestion in 
the cytoplasm into the endoplasmic reticulum for loading onto 
MHC class I molecules (  5, 6  ). Other herpesviruses heavily 
dependent on virus replication to establish a latent viral load, 
such as the     -subfamily human and mouse cytomegaloviruses, 
have likewise been found to possess several CD8     T cell 
evasion mechanisms targeting either TAP or MHC class I 
assembly (  7, 8  ). 
  The situation has been less clear for lymphocryptoviruses 
(LCVs), the most recently evolved (   1) herpesvirus genus, whose 
members are found only in Old World and some New World 
primate species and whose prototype is the EBV of humans. 
These viruses are orally transmitted, replicate in oropharyngeal 
epithelial sites and establish latency in B lymphocytes (for 
review see reference   9  ). When fi  rst colonizing the B cell 
system, LCVs use their unique growth-transforming ability to 
directly drive the expansion of latently infected B cells and 
only later down-regulate latent antigen expression to establish 
an immunologically silent infection of the memory B cell pool 
(  10  ). This ability to expand the latently infected cell reservoir 
independent of lytic virus replication has raised debate as to 
whether LCVs might be under less intense immunological pres-
sure to evade T cell control over the lytic cycle (  11  ). 
  We were prompted to return to this question by two re-
cent fi  ndings in the EBV system, both suggestive of an active 
immune evasion strategy in the lytic cycle. First, cells produc-
tively infected with EBV in vitro showed HLA class I down-
regulation and reduced TAP function (  12  ). Second, in vitro 
assays on lytically infected target cells using CD8     T cell clones 
  Figure 1.     Diagrammatic alignment of the right-hand ends of the sequenced     1-herpesviruses. ORFs of EBV, the rhesus LCV, and marmoset 
LCV are shown as boxes; closed symbols represent ORFs with homologues in other herpesviruses; open symbols represent genes found only in 
    1-herpesviruses; and hatched symbols represent latent genes.     JEM VOL. 204, August 6, 2007 
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depicted) ever gave such an eff  ect.   Fig. 2 A   (bottom) pre-
sents data from an essentially similar assay conducted in an 
EBV-transformed B lymphoblastoid cell line (LCL). In this 
case, the cells were infected with a vaccinia virus encoding, 
as an indicator antigen, an invariant chain  –  tagged form of 
the EBNA3C protein that is processed by the HLA class I 
and class II pathways, thereby allowing both CD8     and 
CD4     T cell recognition to be assayed simultaneously on 
the same target cells. As shown in   Fig. 2 A   (middle), expres-
sion of BNLF2a (and of ICP47) reduced target cell killing 
by an HLA-B*2705  –  restricted EBNA3C-specifi  c CD8     T 
cell clone to the background level seen on unmanipulated 
LCL targets. This background level represents recognition 
of preexisting epitopes derived from EBNA3C expressed 
from the resident EBV genome. In contrast, neither vaccinia 
BNLF2a nor any of the other proteins tested had any eff  ect 
on the presentation of invariant chain  –  tagged EBNA3C 
to a DQ5-restricted EBNA3C-specific CD4     T cell clone 
(  Fig. 2 A  , bottom). 
    Fig. 2 B   shows the results of subsequent experiments con-
ducted using EBV-transformed B cell lines with diff  erent 
HLA alleles to assess any allele-specifi  c eff  ects of BNLF2a 
on CD8     T cell recognition. These assays used several dif-
ferent EBV latent (EBNA2 and EBNA3B) and lytic (BMLF1, 
BMRF1, BZLF1, and BGLF4) target antigens encoding epi-
topes recognized in the context of HLA-A (A*0201 and 
A*2402), HLA-B (B*0801, B*2705, and B*3801), and 
HLA-C (C*0101) molecules. We observed marked inhibi-
tion of target cell killing by BNLF2a throughout such experi-
ments (  Fig. 2 B  ). 
  EBV BNLF2a causes cell-surface HLA class I 
down-regulation 
  To determine the mechanism of BNLF2a-mediated inhibi-
tion of CD8     T cell recognition, BNLF2a containing a hemag-
glutinin (HA) epitope tag (BNLF2aHA) was expressed in 
the melanoma cell line MelJuSo (MJS) through retroviral 
transduction. Initially, we performed cytotoxicity assays on the 
transduced cells to confi  rm that retrovirus-mediated expres-
sion of BNLF2aHA in MJS cells recapitulates the BNLF2a-
induced phenotype described in the previous section.   Fig. 3 A   
shows the results of a cytotoxicity assay using the HLA-
B*0801  –  positive MJS cells expressing either BNLF2aHA or 
GFP as targets.   Infection of MJS cells with recombinant vac-
cinia virus expressing the EBV BZLF1 antigen resulted in 
recognition by BZLF1-specifi  c CD8     T cells (  Fig. 3 A  , top), 
but this was abrogated in BNLF2aHA-expressing MJS cells 
(  Fig. 3 A  , bottom). However, when the target cells were 
sensitized with the relevant synthetic epitope peptide from 
BZLF1 (RAKFKQLL), the cells were lysed equally well 
whether or not BNLF2a was present (  Fig. 3 A  ). These data 
indicate that BNLF2a blocks presentation of antigens that 
  require endogenous processing before being presented to HLA 
class I  –  restricted T cells. 
  Because HLA class I levels have been found to be mark-
edly reduced during productive EBV infection (  12  ), we 
  All six genes were separately cloned into recombinant 
vaccinia virus vectors, as was the immune evasion gene from 
HSV, ICP47, as a positive control. These recombinants 
were then tested for their ability to inhibit CD8     T cell kill-
ing when introduced into target cells along with a second 
vaccinia vector encoding an indicator target antigen. Such 
experiments were performed in the two cell types that EBV 
naturally infects in vivo, epithelial cells and B lymphocytes. 
  Fig. 2 A   (top) presents the results from a representative as-
say in the HLA-B*0801  –  positive epithelial cell line SVK 
using EBV nuclear antigen (EBNA) 3A as the target anti-
gen and a CD8     T cell clone specifi  c for an HLA-B*0801  – 
restricted EBNA3A epitope as the eff  ector.   Expression of 
one of the six EBV genes in question, BNLF2a, reduced 
the level of CD8     T cell killing almost to background levels, 
as did the positive control ICP47. None of the other EBV 
genes tested (including BILF2, BLLF2, and BHLF1; not 
  Figure 2.     Representative cytotoxicity assays testing recognition 
of target cells coexpressing EBV-unique genes and target proteins. 
(A) Epithelial cells (top) were infected with vaccinia viruses expressing 
EBNA3A (vAntigen) and combinations of the indicated viruses expressing 
genes unique to EBV or a control vaccinia virus lacking an inserted 
gene (vTk  −  ), before being incubated with HLA-B*0801  –  restricted CD8    
T cell clones specifi  c for EBNA3A. EBV-transformed B cells (middle and 
bottom) were coinfected with modifi  ed vaccinia Ankara expressing 
  invariant chain  –  targeted EBNA3C (vAntigen) and the indicated combina-
tions of vaccinia viruses. In parallel assays, the infected B cells were 
incubated with either HLA-B*2705  –  restricted CD8     T cell clones specifi  c 
for EBNA3C (middle) or CD4     T cell clones restricted by HLA DQ5 specifi  c 
for EBNA3C (bottom). (B) EBV-transformed B cells were infected with 
vaccinia viruses expressing BNLF2a, and the different EBV antigens indi-
cated (vAntigen) encoding epitopes presented through a range of HLA 
types. Infected cells were incubated with cognate CD8     T cells specifi  c 
for an HLA-A*0201 epitope encoded by BMLF1, an HLA-A*2402 epitope 
encoded by BMRF1, an HLA-B*38 epitope encoded by EBNA2, an HLA-
B*2705 epitope encoded by EBNA3B, an HLA-B*0801 epitope encoded by 
BZLF1, or an HLA-C*0101 epitope encoded by BGLF4. Error bars represent 
means      SD.   1866 CD8     T CELL IMMUNE EVASION BY EBV | Hislop et al.
MJS cells. In control cells, fl  uorescent model peptides were 
effi   ciently transported across the endoplasmic reticulum mem-
brane in an ATP-dependent manner. In contrast, peptide trans-
location was strongly impaired in BNLF2aHA-expressing 
cells (  Fig. 4 A  ).   
  We next investigated whether BNLF2a was associated 
with the peptide-loading complex by performing coimmuno-
precipitation experiments. BNLF2aHA-expressing or control 
cells were lysed using the mild detergent digitonin to pre-
serve protein  –  protein interactions. TAP1, TAP2, tapasin, 
and HLA class I molecules were immunoprecipitated from 
the lysates, and all precipitates were probed with an HA-specifi  c 
mAb to detect BNLF2aHA.   Fig. 4 B   shows that BNLF2a co-
precipitates with TAP1, TAP2, tapasin, and HLA class I mol-
ecules, but not with HLA class II and the transferrin receptor 
(used as controls; TfR data not depicted). 
  EBV BNLF2a blocks TAP function by preventing the binding 
of peptides and ATP 
  TAP-mediated translocation of peptides into the endoplas-
mic reticulum is initiated by the interaction of peptides with 
the cytosolic peptide binding domains of TAP, followed by 
the binding and hydrolysis of ATP, which facilitates the 
opening of the transmembrane pore and peptide transloca-
tion (  14, 15  ). We therefore evaluated the eff  ect of BNL-
F2aHA on these steps in peptide transfer. The ability of peptides 
to bind to TAP in the presence of BNLF2a was examined by 
incubating radiolabeled peptides containing a photoactivat-
able cross-linker with microsomes derived from BNLF2aHA-
expressing or control MJS cells. Peptides were covalently 
linked to their binding partners by UV irradiation and 
then separated by PAGE. In control MJS cells, radiolabeled 
peptides covalently linked to TAP were observed (  Fig. 5 A  ; 
expressed as 100% in the quantitation depicted in   Fig. 5 B  ), 
whereas such peptides failed to bind TAP in microsomes 
next examined whether expression of BNLF2a aff  ected the 
display of HLA molecules (  Fig. 3 B  ). At the surface of trans-
duced MJS cells, levels of HLA class I were substantially 
reduced on BNLF2aHA-expressing cells compared with con-
trol cells. This was a specifi  c eff  ect, because expression of 
HLA class II (  Fig. 3 B  ) and transferrin receptor (not depicted) 
were unaff  ected. 
  Down-regulation of surface HLA class I molecules can 
result from viral interference at specifi  c stages of the class I 
antigen presentation pathway and may involve the degrada-
tion of HLA class I molecules and other components of the 
HLA class I peptide-loading complex (  7, 8  ). To investigate 
whether BNLF2a aff   ects levels of the components of the 
HLA class I peptide-loading complex, lysates of BNLF2aHA 
or control transduced MJS cells were subjected to Western 
blot analysis for TAP1, TAP2, tapasin, and HLA class I. No 
marked diff  erences were observed in the steady-state levels of 
these proteins (  Fig. 3 C  ). Thus, despite reduced surface HLA 
class I levels, cells expressing BNLF2aHA contained similar 
levels of the major components of the HLA class I peptide-
loading complex. 
  EBV BNLF2a blocks peptide transport by TAP 
  Surface HLA class I down-regulation can also result from the 
reduced supply of peptides to nascent HLA class I molecules 
in the endoplasmic reticulum. This is turn relies on the effi   -
cient generation of peptides by the proteasome and other 
peptidases and the transport of these peptides in to the endo-
plasmic reticulum by the TAP complex. In EBV-infected B 
cells that have entered the virus lytic cycle, surface HLA class I 
down-regulation coincides with reduced peptide transport 
by TAP (  12  ). To evaluate whether the inhibition of HLA 
class I expression by BNLF2a involves interference with TAP 
function, we used an in vitro peptide translocation assay to 
examine TAP activity in BNLF2aHA-expressing and control 
  Figure 3.     Expression of BNLF2a prevents CD8     T cell recognition by disrupting antigen presentation. (A) MJS cells were retrovirally transduced 
to express BNLF2aHA (bottom) or control GFP (top). These cells were either infected with vaccinia viruses expressing BZLF1 or a control TK  −   virus, or 
  sensitized with RAKFKQLL peptide or DMSO as a control before being incubated with CD8     T cells specifi  c for the BZLF1-encoded RAKFKQLL epitope in 5-h 
cytotoxicity assays. Error bars represent means      SD. (B) Flow cytometry histograms of the same cell lines show surface staining for HLA class I (B9.12.1) 
and HLA class II (L243), or staining with an isotype control. (C) Lysates of the two cell lines were separated by SDS-PAGE and analyzed by immunoblotting 
with antibodies specifi  c for the HA tag (12CA5), TAP1 (148.3), TAP2 (435.4), tapasin (7F6), HLA class I heavy chains (HC10), and HLA class II DR    
chains  (DA6-147).   JEM VOL. 204, August 6, 2007 
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in digitonin or NP-40 (  Fig. 5 C  , lanes 1 and 3), whereas 
tapasin and HLA class I molecules were coisolated only with 
ATP-bound TAP recovered from digitonin lysates (  Fig. 5 C  , 
compare lane 1 with lane 3). In contrast, the ATP-bound 
fraction from digitonin lysates of BNLF2aHA-expressing 
cells contained little of the four components of the peptide-
loading complex (  Fig. 5 C  , lane 2), indicating that the EBV 
protein inhibits the interaction of ATP with the TAP pro-
teins. Accordingly, BNLF2aHA was not detected in the 
ATP-agarose pellet fraction (lane 2) but was present in the 
supernatant fraction of BNLF2a-transduced MJS cells (lane 6). 
Interestingly, BNLF2a was released from TAP in NP-40 
lysates, which restored the ATP-binding capacity of the TAP 
subunits, implying a low-affi   nity interaction of BNLF2a with 
TAP that prevents binding to ATP-agarose beads (lane 4). 
  BNLF2a homologues are encoded by other Old World     1 
primate herpesviruses and down-regulate HLA 
class I expression 
  Because earlier genomic alignments had shown that a BNLF2a 
homologous gene was present in the Rhesus LCV genome, 
we went on to sequence the equivalent region from the 
LCV genomes of baboons (papio herpesvirus), chimpanzees 
(pan herpesvirus), orangutans (orangutan herpesvirus), and 
gorillas (gorilla herpesvirus). Each virus genome contained an 
equivalent BNLF2a open reading frame (ORF).   Fig. 6 A   
shows the predicted amino acid sequence of these homolo-
gous proteins alongside those of EBV and the rhesus macaque 
LCV.   These proteins show between 53 and 63% overall 
identity and share similar features; they are small 59  –  60  –
  amino acid proteins, and each has a hydrophobic C terminus 
and several sites in the nonhydrophobic region where the se-
quence is conserved. Homology or alignment searches using 
programs such as the basic local alignment search tool reveal 
no obvious matches with any other protein in the database 
(unpublished data). 
  To test whether the BNLF2a homologues within the 
nonhuman LCVs had retained BNLF2a-like function, the 
relevant coding sequences were introduced into plasmid expres-
sion vectors under the control of the CMV immediate early 
promoter and transiently transfected into the human MJS cell 
line. Plasmid constructs were engineered to coexpress GFP 
using an internal ribosome entry site (IRES) element allowing 
identifi  cation of transfected cells.   Fig. 6 B  shows the fl  ow cyto-
metric analysis of MJS cells that had been transfected with 
the BNLF2a genes derived from EBV, the rhesus LCV, pan 
herpesvirus (note that the pan and orangutan BNLF2a genes 
had identical sequences), or gorilla herpesvirus. Cells were 
stained for surface HLA class I or surface HLA class II as a 
control. In each case, expression of BNLF2a derived from 
the diff  erent viruses reproducibly caused down-regulation of 
surface HLA class I to diff  erent degrees depending on the species 
from which the gene was derived, whereas HLA class II levels 
were unaff  ected. 
  We subsequently extended these studies by transfecting 
other available Old World primate cell lines with the diff  erent 
from BNLF2aHA-expressing cells (  Fig. 5, A and B  ).   As a 
specifi  city control, microsomes were incubated with both the 
radiolabeled reporter peptide and an unlabeled peptide de-
rived from the HSV-1 ICP47 protein that is known to pre-
vent peptide binding to TAP (  16, 17  ). No binding of the 
radiolabeled peptide to TAP was observed in the presence of 
the ICP47 peptide (  Fig. 5, A and B  ). 
  We next asked whether BNLF2a might also aff  ect the 
binding of ATP to TAP. Lysates of BNLF2aHA-transduced 
or control cells were made using either the detergents digito-
nin, which preserves protein interactions within the peptide-
loading complex, or 1% NP-40, which releases HLA class I, 
tapasin, and BNLF2a from TAP (see later in this section). 
Proteins capable of binding ATP were purifi  ed from the 
lysates by incubation with ATP-agarose beads and pelleting; 
these fractions, as well as the nonbinding supernatant (free) 
fractions, were subjected to Western blot analysis for the presence 
of TAP1, TAP2, tapasin, HLA class I, or   BNLF2aHA. In con-
trol cells, ATP binds to the TAP subunits solubilized either 
  Figure 4.     EBV BNLF2a blocks peptide transport by TAP. (A) TAP-
dependent peptide transport in BNLF2aHA-expressing and control MJS 
cells was assessed by permeabilizing the cells with streptolysin O and 
incubating them with a fl  uoresceinated peptide in the presence or ab-
sence of ATP. Translocated peptides that had become glycosylated in the 
endoplasmic reticulum were recovered by adsorption to concanavalin 
A  –  sepharose beads. After elution, the recovered peptide was quantitated 
by fl  uorometry in arbitrary units. Error bars represent the SEM of triplicates 
in a representative experiment. (B) Digitonin lysates of BNLF2aHA-
  expressing and control MJS-GFP cells were subjected to immunoprecipi-
tation (IP) with antibodies specifi  c for TAP1 (148.3), TAP2 (435.4), tapasin 
(R.gp46C), HLA class I heavy chains (HC10), and HLA class II DR     chains 
(DA6-147). Cell lysates and immune complexes were separated by 
SDS-PAGE, followed by Western blot analysis and staining with anti-HA 
antibody (12CA5) to detect HA-tagged BNLF2a.     1868 CD8     T CELL IMMUNE EVASION BY EBV | Hislop et al.
  Noting that immune evasion strategies within the herpes-
virus family tend to be virus subfamily or genus specifi  c, we 
focused on the six lytic cycle genes that were unique to the 
    1 genus and of unknown function. This identifi  ed one such 
gene, BNLF2a, as encoding a CD8 immune evasion protein. 
When expressed from a vaccinia vector in target cells, the 
BNLF2a protein reproducibly inhibited recognition of vari-
ous indicator antigens (EBV latent and lytic cycle proteins) by 
CD8     T cell clones restricted through several HLA-A, -B, 
and -C alleles. In contrast, class II antigen presentation in 
BNLF2a-expressing cells remained intact, and only presenta-
tion by the HLA class I pathway was impeded. The BNLF2a 
protein was found to function by blocking both peptide and 
ATP binding to the TAP complex, thereby impairing pep-
tide loading of HLA class I molecules and their expression at 
the cell surface. 
  It is notable that BNLF2a transcripts initially appear in the 
early phase of the lytic cycle, peaking 8  –  12 h after lytic cycle 
induction in a B cell line (  18  ). The majority of EBV lytic cycle 
transcripts are expressed in the late phase after BNLF2a expres-
sion, at a time when the protein  ’  s eff  ects are likely to be well 
established. This would explain why the late proteins are poorly 
processed and presented by lytically infected cells. In contrast, 
the two immediate early proteins, BZLF1 and BRLF1, ex-
pressed in the first wave of viral gene expression before 
BNLF2a are effi   ciently recognized by their cognate T cells (  13  ). 
The less effi   cient presentation of the four early antigens tested 
in our previous study (13) likely refl  ects the fact that they 
are expressed before BNLF2a  ’  s inhibitory eff  ects are optimal. 
These antigens are known to be BZLF1/BRLF1 induced and, 
therefore, appear very soon after the immediate early-to-early 
transition, probably just before BNLF2a expression (  19  –  23  ). 
  It is also interesting to note how the actions of BNLF2a 
might explain the highly skewed composition of the lytic 
BNLF2a genes and measuring the surface MHC class I levels 
of the transfected cells as before. Fig. S1 (available at http://
www.jem.org/cgi/content/full/jem.20070256/DC1) shows 
histograms of MHC class I staining of transfected LLC-MK2 
cells (Rhesus macaque), orangutan B cells transformed with 
the endogenous orangutan herpesvirus (orangutan LCL), and 
Cos cells (African green monkey). All BNLF2a expression 
constructs showed down-regulation of surface MHC class I 
in LLC-MK2 cells and Cos cells, with a more subtle down-
regulation observed in transformed orangutan LCLs. The 
inhibitory eff  ects of the various LCV BNLF2a proteins there-
fore appear to be conserved and operate in various cells of Old 
World primate origin. 
    DISCUSSION   
  This study was prompted by recent work (  13  ) looking into 
target cell recognition by CD8     T cell clones specifi  c for 
EBV  –  lytic cycle antigens. This had shown that recognition 
was most effi   cient using clones against immediate early anti-
gens, less so for clones against early antigens, and much less so 
for late antigen  –  specifi  c eff  ectors, despite the fact that the lat-
ter had the highest avidity in epitope peptide titration assays 
(  13  ). Therefore, antigen processing function appeared to be 
progressively impaired as cells moved through the lytic cycle. 
Two observations argued against this being a secondary eff  ect 
of general cytopathology associated with virus replication. 
Thus, in B LCLs in vitro where a small percentage of cells 
enter the lytic cycle, cells in the late phase of virus replication 
appear to remain viable for several days. More importantly, 
surface HLA class I levels on lytically infected cells begin to 
fall in the early phase of the cycle before other surface pro-
teins, including HLA class II, are aff  ected (  12  ). This implied 
that EBV was actively impeding lytic cycle antigen presenta-
tion to CD8     T cells. 
  Figure 5.     EBV BNLF2a inhibits peptide and ATP binding to TAP. (A) Microsomes prepared from BNLF2aHA-expressing and control MJS cells 
were incubated with a radiolabeled model peptide; where indicated, an excess of ICP47 competitor peptide was included in this incubation. After UV 
cross-linking, microsomes were lysed, and the proteins were separated by SDS-PAGE and exposed to a phosphoimaging screen. The position where 
TAP1 migrated in parallel immunoprecipitation experiments is shown by the arrowhead. The asterisk denotes a nonspecific background band. 
(B) Quantifi  cation of triplicate bands representing TAP-bound peptide. Results are shown as the percentage of peptide binding relative to peptide 
binding in control MJS cells (set as 100%). Error bars represent means      SD. (C) Digitonin and NP-40 lysates of MJS-BNLF2aHA and control MJS-GFP 
cells were incubated with ATP-agarose beads. ATP-agarose  –  bound (pellet) and unbound (supernatant) protein fractions were separated by SDS-PAGE 
and immunoblotted. Membranes were probed with antibodies specifi  c for TAP1 (148.3), TAP2 (435.4), tapasin (7F6), HLA class I heavy chain (HC10), 
and the HA tag (12CA5).     JEM VOL. 204, August 6, 2007 
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cells in selectively amplifying responses to epitopes that are well 
presented on those target cells. 
  BNLF2a is one of a set of genes, including two others with 
immunomodulatory function, BCRF1 (viral IL-10 homo-
logue) and BARF1 (viral GCSF-receptor), that have been ac-
quired by the     1 viruses of Old World primates but are absent 
from the New World     1 virus analyzed thus far (  27, 28  ). This 
implies acquisition, in the last 50 million years or so, after the 
Old World/New World fork in primate evolution. The Old 
World primate viruses have also acquired a more complex set 
of latent growth-transforming genes over this same period. 
Thus, it may be the combination of these more sophisticated 
immune-evasion and growth-transforming strategies that un-
derlies the apparently greater prevalence that the Old World 
viruses achieve in their host population compared with their 
New World counterpart (  29  ). 
  BNLF2a is the fi  rst TAP-specifi  c inhibitor identifi  ed in 
    1-herpesviruses, and like the other three herpesvirus TAP in-
hibitors identifi  ed so far, BNLF2a has its own unique structure 
and mechanism of action. Simplexviruses and varicellovi-
ruses, both members of the      subfamily, use diff  erent strategies 
antigen-induced CD8     T cell response to EBV infection, 
whereby antigens expressed before or at the latest coincident 
with BNLF2a during the course of the lytic cycle constitute by 
far the most dominant targets. Thus when we derived CD8     T 
cell clones from the expanded CD8     population of IM patients 
in an unbiased manner, we often identifi  ed strong CD8 reac-
tivities specifi  c for the two immediate early proteins and for 
a small subset of early proteins, but only rarely to other early 
proteins or to any of the late proteins analyzed (  11, 13  ). Simi-
larly, when T cells were cloned from the joints of rheumatoid 
arthritis patients and tested against an EBV-cDNA expression 
library, only T cells specifi  c for immediate early or a small 
number of early proteins were detected (  24, 25  ). Thus, very 
few responses to late proteins have been described and, when 
they occur, these responses are weak (  26  ). Yet, in principle, all 
lytic cycle proteins should be available as exogenous antigens 
for cross-presentation by dendritic cells during the priming of 
the CD8     T cell response. We infer that, after priming, the sub-
sequent numerical dominance of immediate early and early 
antigen-specifi  c responses refl  ects the importance of direct con-
tact between primed CD8     T cells and lytically infected target 
  Figure 6.     Old World primate     1-herpesvirus BNLF2a sequence and function. (A) The BNLF2 regions from the indicated herpesviruses were 
sequenced, and the predicted amino acid sequence of the BNLF2a genes are shown. Black regions represent regions of homology between the different 
BNLF2a species, whereas gray-shaded regions represent conservative amino acid changes. (B) BNLF2a genes were subcloned into plasmid expression 
  vectors that coexpressed GFP, and these were transiently transfected into MJS cells. At 48 h, surface levels of HLA class I and class II were assessed on 
GFP-positive cells by staining with the relevant antibody and analyzing the cells by fl  ow cytometry. Black histograms represent surface marker intensity 
of cells transfected with the relevant BNLF2a, whereas open histograms represent the intensity of cells transfected with the empty vector plasmid.     1870 CD8     T CELL IMMUNE EVASION BY EBV | Hislop et al.
in their ability to be lysed by CD8     T cells. Interesting in 
this context is the recent identifi  cation of the EBV-encoded 
gene BGLF5, which is at least one gene responsible for host 
protein synthesis shutoff   (  49  ). Expression of BGLF5 is suf-
fi  cient to inhibit synthesis of host proteins, including HLA 
class I molecules, causing a decrease in surface class I levels. 
Coexpression of BNLF2a and BGLF5 by EBV could then 
represent an eff  ective strategy for inhibiting the HLA class I 
antigen processing pathway (  12  ). 
  In summary, the prototype     1-herpesvirus, EBV, evades 
CD8     T cell detection in the lytic cycle through a strategy that 
is unique in its molecular detail yet targets antigen presenta-
tion at the same point, TAP-mediated peptide transport, that 
is targeted by several other herpesviruses. The fact that the 
TAP inhibitors encoded by the diff  erent herpesvirus genera 
share no obvious homology presents a striking example of 
convergent evolution. Their existence testifi  es to the strength 
of the evolutionary pressure exerted on many herpesviruses 
by CD8     T cell responses against virus replicative infections. 
The present work indicates that, despite their ability to amplify 
viral loads in vivo through nonreplicative latent infection, 
EBV and Old World     1-herpesvirus relatives have indeed 
been subjected to the same immune pressure. 
  MATERIALS AND METHODS 
  CD8     T cell clones, vaccinia viruses, and cytotoxicity assays.     EBV-
specifi  c CD8     T cell clones were generated from PBMCs of infectious 
mononucleosis patients by limiting dilution cloning, as previously described 
(  11  ). CD8     T cell clones used in this study were specifi  c for the follow-
ing epitopes derived from the respective EBV gene products: RAKFKQLL 
from BZLF1 and QAKWRLQTL from EBNA3A (both presented by HLA-
B*0801 [  50, 51  ]), GLCTLVAML from BMLF1 (presented by HLA-A*0201 
[  11  ]), CYDHAQTHL from BMRF1 (presented by HLA A*2402 [  13  ]), 
YHLIVDTDSL from EBNA2 (presented by HLA-B*38 [  52  ]), HRCQA-
IRKK from EBNA3B (presented by HLA-B*2705 [  53  ]), and an undefi  ned 
epitope derived from BGLF4 (presented by HLA-C*0101 [ 13  ]). CD4     T cell 
clones specifi  c for the HLA DQ5  –  presented epitope SDDELPYIDPNMEP 
from EBNA 3C were produced by the stimulation of PBMCs from healthy 
donors, with their autologous EBV-transformed B cell line and limiting 
dilution cloning these cells, as previously described (  54  ). All experiments 
were approved by the South Birmingham Health Authority Local Research 
Ethics Committee. Recombinant vaccinia viruses were used to express indi-
vidual EBV B95.8 strain genes, as previously described, and a vaccinia virus 
lacking an insert (vTk  −  ) used for control infections (  13, 54  ). Target cells 
infected with the vaccinia viruses for cytotoxicity assays were either SV40-
transformed keratinocytes, HLA-matched EBV-transformed B LCLs, or the 
melanoma cell line MJS (HLA-A*01, -B*08, and -Cw*07) (  55  ). Target cells 
were infected with vaccinia viruses at a multiplicity of infection of 10, incu-
bated for 16 h, and used as targets in standard 5-h chromium release assays. 
Where indicated in the fi  gures, target cells were sensitized with synthetic 
CTL epitope peptide (Alta Biosciences) at a concentration of 5     M for 90 min 
before use in cytotoxicity assays. 
  Antibodies.     The antibodies used in this study have been described else-
where (  32, 55  ). Mouse mAbs used to detect human cellular proteins were as 
follows: W6/32 or B9.12.1, which recognizes       2  -microglobulin  –    associated 
HLA class I complexes (Immunotech); HC10 (provided by H. Ploegh, 
Whitehead Institute for Biomedical Research, Cambridge, MA), specifi  c for 
HLA class I heavy chains; anti  –  HLA-DR mAb L243 (American Type Culture 
Collection); DA6-147, specifi  c for HLA-DR     chains (provided by P. Cresswell, 
Howard Hughes Medical Institute, Yale University School of Medicine, 
New Haven, CT); and 148.3 directed to TAP1 and 435.4 directed to TAP2 
to inactivate TAP. The simplexviruses HSV1 and 2 encode a 
small cytosolic protein, ICP47, which acts as a high affi   nity 
competitor for peptide binding to TAP yet does not aff  ect 
ATP binding to the transporter complex (  5, 6, 17, 30, 31  ). 
In contrast, the varicellovirus bovine herpesvirus 1 and sev-
eral of its relatives encode the UL49.5 gene product, which 
renders TAP translocation incompetent without aff  ecting 
its ability to bind peptide or ATP (  32, 33  ). Ultimately, bovine 
herpesvirus 1 UL49.5 targets TAP1 and TAP2 for degradation 
by proteasomes (  32, 33  ). In the case of     -herpesviruses, the 
prototypic virus of this subfamily, human CMV, inhibits TAP 
function via the endoplasmic reticulum luminal domain of the 
transmembrane protein US6. This protein reduces association 
of ATP to TAP1 and promotes binding to TAP2 but does not 
interfere with peptide binding, nor does it infl  uence the stability 
of the transporter complex (  34  –  38  ). In the case of the     2-
herpesvirus, mouse       −  herpesvirus 68, TAP is targeted second-
arily for slow degradation by the virus-encoded ubiquitin 
ligase mK3, whose primary function is to rapidly target MHC 
class I heavy chains for proteasomal degradation (  39  –  46  ). 
  In contrast to the described TAP inhibitors in the other 
herpesviruses, BNLF2a disables TAP function by blocking both 
the association of peptides with the peptide binding site and the 
interaction of ATP with the nucleotide binding domains of the 
transporter. How this small 60  –  amino acid protein, which con-
sists of a hydrophilic N-terminal domain of 42 residues and a 
hydrophobic domain of 18 residues, achieves both of these 
functions is currently unclear. Despite the absence of an obvi-
ous N-terminal signal sequence, preliminary data suggest that 
BNLF2a is membrane-associated (unpublished data). This may 
be a consequence of binding to TAP or may result from post-
translational insertion of the hydrophobic C terminus into the 
endoplasmic reticulum membrane, as has been reported for 
other proteins (  47  ). The small size of BNLF2a and the relative 
distance between the peptide and ATP binding sites of TAP 
may preclude BNLF2a from acting directly on both of these 
sites. The expected exposure of BNLF2a  ’  s N terminus in the 
cytosol would, however, suggest that this part interacts with cyto-
solic domains of the TAP complex. BNLF2a may then inter-
fere directly with peptide or ATP binding while simultaneously 
disrupting subsequent steps of the translocation cycle through 
an indirect mechanism, e.g., by inhibiting conformational tran-
sitions required for proper function of the TAP complex. 
  The ability of an infected cell to escape CD8     T cell 
recognition is likely to be most effi   cient when multiple 
points of the antigen processing pathway are targeted by 
viral immune evasion proteins. In the case of HSV2-infected 
cells, two viral proteins, the TAP inhibitor ICP47 and the 
host shutoff   protein encoded by UL-41, have been shown 
to act synergistically to prevent CD8     T cell lysis (  48  ). In 
such an infection model, the long-lived TAP complexes are 
unlikely to be aff  ected in the short term by the virus host 
shutoff   function. Thus, cells infected with mutant HSV vi-
ruses lacking either of these two genes show partial inhibi-
tion of CD8     T cell function, whereas cells infected with 
viruses expressing both genes show a dramatic reduction JEM VOL. 204, August 6, 2007 
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(ERYDKSE-[BPA]-L [  57  ]) containing a photoactivatable cross-linker in the 
absence or presence of 2.5     M of unlabeled HSV-1 ICP47 competitor pep-
tide (  16  ). After incubation for 15 min on ice, microsomes were washed with 
PBS, and peptide  –  protein interactions were covalently linked by UV expo-
sure for 10 min on ice at a distance of 2 cm using a UVP lamp (B-100A; 
Blak-Ray) with a mercury lamp (Par 38; Sylvania). Samples were analyzed by 
SDS-PAGE, and bound peptide was quantitated by phosphoimaging. Migra-
tion of peptide-bound TAP1 was confi  rmed by immunoprecipitation. 
  ATP-agarose binding assay.     MJS cells transduced with BNLF2aHA or 
GFP were lysed with 1% digitonin or 1% NP-40, as described in Western 
blot analysis and immunoprecipitations. Nuclei were removed, and lysates 
were incubated with hydrated C-8 ATP-agarose beads (13-    M; fi  nal con-
centration; Sigma-Aldrich) at 4  °  C for 2 h. The beads were centrifuged to 
provide a supernatant fraction and a pellet fraction. Proteins bound to the 
ATP-agarose pellet fraction were eluted with 500 mM EDTA, and these as 
well as the supernatant fraction were analyzed by Western blot. 
  Cloning and transient expression of BNLF2a genes.     BNLF2a homo-
logues were cloned from the following LCVs: papio herpesvirus, rhesus her-
pesvirus, pan herpesvirus, orangutan herpesvirus, and gorilla herpesvirus. 
PCR primers were designed to hybridize to a sequence fl  anking the BNLF2 
region, which was conserved between EBV and the rhesus herpesvirus. 
PCR products were amplifi  ed from either a genomic DNA fragment of 
rhesus herpesvirus (provided by F. Wang, Harvard Medical School, Boston, 
MA) or from DNA extracted from B cell lines spontaneously transformed 
with the endogenous LCV of each host species. This amplifi  ed BNLF2 re-
gion of each virus was cloned into the plasmid pCR2.1TOPO (Invitrogen), 
and inserts were sequenced using standard techniques. Sequences are avail-
able from GenBank/EMBL/DDBJ under accession nos.   EF207711   (papio 
herpesvirus),   EF207712   (pan herpesvirus),   EF207713   (orangutan herpesvirus), 
and   EF207714   (gorilla herpesvirus). 
  For functional studies, the BNLF2a genes were subcloned into a modi-
fi  ed pCDNA3 vector (provided by E. Reits) and expressed under the con-
trol of the CMV immediate early promoter. Immediately downstream from 
BNLF2a was an IRES element followed by the GFP gene, allowing co-
expression of this marker. Plasmids were transfected into either MJS cells, 
the Rhesus macaque kidney cell line LLC-MK2, or the African green monkey 
kidney fi  broblast like cell line Cos using Lipofectamine 2000 (Invitrogen), or 
transfected by electroporation into orangutan B cells transformed with their 
endogenous LCV. Transfected cells were cultured for 48 h before staining 
for surface marker expression and fl  ow cytometric analysis, as described in 
Flow cytometry analysis of surface HLA class I and II. 
  Online supplemental material.     Fig. S1 shows histograms of the fl  uores-
cence intensity of MHC class I staining on Old World primate cells transfected 
with plasmids expressing BNLF2a homologues. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20070256/DC1. 
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